Free Trial
NASDAQ:RNXT

RenovoRx Q1 2024 Earnings Report

RenovoRx logo
$1.30 +0.06 (+4.44%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.10 (+7.72%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RenovoRx EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Friday, May 10, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

RenovoRx's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

RenovoRx Earnings Headlines

Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright
RenovoRx's (RNXT) "Buy" Rating Reaffirmed at HC Wainwright
Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to Trump’s economic plan. But now there’s a way to protect your retirement without backing down. This free 2025 Wealth Protection Guide reveals how you can use a legal IRS loophole—nicknamed “Piggy Bank”—to shield your savings.
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT), a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

View RenovoRx Profile

More Earnings Resources from MarketBeat